Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Rigel Pharmaceuticals Inc RIGL

Healthcare Biotechnology
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the... see more

Recent & Breaking News (NDAQ:RIGL)

Rigel to Present at the Jefferies London Healthcare Conference

PR Newswire 3 days ago

Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update

PR Newswire 8 days ago

Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition

PR Newswire 10 days ago

Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update

PR Newswire October 31, 2024

Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for GAVRETO® (pralsetinib)

PR Newswire October 24, 2024

Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

PR Newswire October 4, 2024

Rigel to Present at the 2024 Cantor Global Healthcare Conference

PR Newswire September 12, 2024

Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML

PR Newswire September 5, 2024

Rigel Expands Relationship with Kissei to include REZLIDHIA® (olutasidenib) in Japan, the Republic of Korea and Taiwan

PR Newswire September 3, 2024

Rigel to Participate in Upcoming September Investor Conferences

PR Newswire August 29, 2024

Rigel Reports Second Quarter 2024 Financial Results and Provides Business Update

PR Newswire August 6, 2024

Rigel Announces Conference Call and Webcast to Report Second Quarter 2024 Financial Results and Business Update

PR Newswire July 30, 2024

Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

PR Newswire July 12, 2024

Rigel Announces Reverse Stock Split

PR Newswire June 25, 2024

Rigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug Application

PR Newswire June 24, 2024

Rigel Announces Five Presentations at the EHA2024 Hybrid Congress

PR Newswire June 14, 2024

Rigel Highlights New Data in Three Poster Presentations at the 2024 ASCO Annual Meeting

PR Newswire June 3, 2024

Rigel to Present at the Jefferies Global Healthcare Conference

PR Newswire May 30, 2024

Rigel Announces Presentations at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress

PR Newswire May 23, 2024

Rigel Reports First Quarter 2024 Financial Results and Provides Business Update

PR Newswire May 7, 2024